Jianlin Xu
Overview
Explore the profile of Jianlin Xu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
123
Citations
1059
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhang Y, Xu Y, Xu J, Zhong H, Xia J, Zhong R
Cancer Sci
. 2024 Dec;
116(3):753-763.
PMID: 39741120
Third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is the standard therapy for patients harboring T790M after first-generation EGFR-TKI resistance. However, the impact of acquired EGFR amplification on the...
2.
Xun C, Li H, Hu Y, Gao S, Xu J, Wang Y, et al.
J Orthop Surg Res
. 2024 Dec;
19(1):883.
PMID: 39726002
Objectives: This study compared the clinical outcomes of minimally invasive surgery (MIS) and open surgery (OS) for patients with intraspinal tumors. Methods: A systematic search of PubMed, Cochrane Library, EMBASE,...
3.
Zheng L, Hu F, Nie W, Lu J, Zhang B, Xu J, et al.
Cancer Med
. 2024 Sep;
13(17):e70223.
PMID: 39258530
Background: The 9th edition of the TNM Classification for lung cancer delineates M1c into two subcategories: M1c1 (Multiple extrathoracic lesions within a single organ system) and M1c2 (Multiple extrathoracic lesions...
4.
Cheng L, Xu L, Yuan H, Zhao Q, Yue W, Ma S, et al.
Integr Cancer Ther
. 2024 Aug;
23:15347354241268064.
PMID: 39155544
Background: Jianpi Jiedu Recipe has been used to treat digestive tract tumors in China since ancient times, and its reliability has been proven by clinical research. Currently, the specific biological...
5.
Xu Y, Zhang Y, Qiang H, Zhong H, Xu J, Zhong R
Lung Cancer
. 2024 Jul;
194:107892.
PMID: 39018704
Background: The predictive value of programmed death-ligand 1 (PD-L1) expression for the efficacy of tyrosine kinase inhibitors (TKIs) in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC) remains underexplored....
6.
Hu Y, Zhang Y, Lu Y, Xu Y, Xu J, Zhong H, et al.
Respir Res
. 2024 Jun;
25(1):233.
PMID: 38840238
Background: There is inconclusive evidence to suggest that the expression of programmed cell death ligand 1 (PD-L1) is a putative predictor of response to EGFR-TKI therapy in advanced EGFR-mutant non-small...
7.
Ou J, Cui W, Zhao Y, Tang Y, Williams A, Wasalathanthri D, et al.
Biotechnol Prog
. 2024 May;
40(5):e3477.
PMID: 38699906
Media preparation parameters contribute significantly to media quality, cell culture performance, productivity, and product quality. Establishing proper media preparation procedures is critical for ensuring a robust CHO cell culture process....
8.
Zheng L, Hu F, Huang L, Lu J, Yang X, Xu J, et al.
J Immunother Cancer
. 2024 Apr;
12(4).
PMID: 38641349
Background: Combining immune checkpoint inhibitors (ICIs) with chemotherapy has become a standard treatment for patients with non-small cell lung cancer (NSCLC) lacking driver gene mutations. Reliable biomarkers are essential for...
9.
Chen D, Xu J, Zhao Y, Han B, Zhong R
Cancer Biol Ther
. 2024 Mar;
25(1):2331273.
PMID: 38536706
Background: To investigate the influence of pretreatment neutrophil-to-lymphocyte ratio (NLR) and procalcitonin (PCT) on progression-free survival (PFS) in extensive-stage small-cell lung cancer (SCLC) patients. Method: A total of 100 extensive-stage...
10.
Xu Y, Ji H, Zhang Y, Xiong L, Han B, Zhong H, et al.
Oncologist
. 2024 Mar;
29(7):e932-e940.
PMID: 38529688
Background: The efficacy of neoadjuvant treatment with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) monotherapy in patients with stage III-N2 EGFR-mutant remains unsatisfactory. This study explored the potential benefits...